Somaxon’s Silenor Phase 3 Clinical Data Accepted for Publication in Sleep, Sleep Medicine Journals

Published July 23, 2010

Somaxon’s Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the company’s product …
Read more on News-Medical-Net